This model applies well in the setting of TP53 wild-type lymphoproliferative neoplasms, where aggressive lymphomas such as DLBCLs, characterized by high ribosomal biogenesis rates [107], can be cured with standard R-CHOP polychemotherapy [84–86], whereas indolent B cell non-Hodgkin lymphomas (such as small lymphocytic lymphoma/chronic lymphoid leukemia, marginal zone lymphoma, and follicular lymphomas), characterized by low ribosomal biogenesis rates [107], are virtually incurable with the same type of polychemotherapy [89]. The gene discussed is TP53; the disease is lymphoid leukemia.